摘要
目的:评价单药多西他赛作为二线治疗对晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法:33例经病理和(或)细胞学检查诊断为晚期非小细胞肺癌,曾用含有铂类方案化疗,治疗后复发或进展接受多西他赛75mg/㎡静滴1小时,第一天,每3周重复。结果:可评价疗效33例中,无完全缓解(CR),部分缓解(PR)12.1%(4∕33),稳定(SD)51.5%(17∕33),进展(PD)36.4%(12∕33),有效率12.1%(4∕33),中位生存期8.5个月,1年生存率33.3%(11∕33)。不良反应主要是血液学毒性,可以耐受。结论:多西他赛单药用于二线化疗治疗晚期非小细胞肺癌疗效肯定,耐受性较好。
Objective：To evaluate the single-agent docetaxel as second-line treatment of advanced non -small cell lung cancer （NSCLC） treatment and adverse reactions. Methods ： Thirty three patients with advanced non - small cell lung cancer were treated by platinum - containing chemotherapy, if relapse or progress after treatment to receive docetaxel 75mg / m^2 intravenous infusion of 1 hour,the first day repeat every 3 weeks. Results：All 33 cases could be evaluated,no complete remission （CR） ,partial remission （PR） was 12.1% （4/ 33）, stable （SD） 51.5% （17/ 33） ,progress （PD）36.4% （12/33 ） ,effective rate was 12.1% （4/33 ） ,the median survival time 8.5 months, one year survival rate 33.3% （11/33）. Adverse reactions were mainly hematological toxicity,but patients can be tolera-ted. Conclusion ： The single - agent docetaxel for second - line chemotherapy for advanced non - small cell lung canc-er is effective and with a better tolerability.
出处
《现代肿瘤医学》
CAS
2012年第9期1866-1868,共3页
Journal of Modern Oncology
关键词
多西他赛
二线治疗
晚期
非小细胞肺癌
docetaxel
second - line treatment
advanced
non - small cell lung cancer
